Drugs
Conditions
News and resources
Humira (adalimumab) is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS who have objective signs of inflammation (elevated CRP and/or MRI) and who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).
In the Phase III trial (ABILITY-1), patients with active non-radiographic axial spondyloarthritis were randomised to receive either adalimumab (n=91) 40mg by subcutaneous injection or placebo (n=94) every other week for 12 weeks.
Significant improvement in disease signs and symptoms, defined as a minimum 40% improvement from baseline in the Assessment of SpondyloArthritis International Society (ASAS) response criteria, was seen at week 12 in a greater proportion of the adalimumab group than the placebo group (36% vs 15%, p<0.001).
View Humira drug record
Further information: AbbVie Ltd
Follow MIMS on Twitter
In the Phase III trial (ABILITY-1), patients with active non-radiographic axial spondyloarthritis were randomised to receive either adalimumab (n=91) 40mg by subcutaneous injection or placebo (n=94) every other week for 12 weeks.
Significant improvement in disease signs and symptoms, defined as a minimum 40% improvement from baseline in the Assessment of SpondyloArthritis International Society (ASAS) response criteria, was seen at week 12 in a greater proportion of the adalimumab group than the placebo group (36% vs 15%, p<0.001).
View Humira drug record
Further information: AbbVie Ltd
Follow MIMS on Twitter
